Trial · NCT03100344
Results by group404
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 404
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 24 | Placebo | -58.4 | Standard Deviation 31.99 | percentage change | |
| Percent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 24 | Nemolizumab (10 mg) | -72.2 | Standard Deviation 25.96 | percentage change | |
| Percent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 24 | Nemolizumab (30 mg) | -73.4 | Standard Deviation 29.67 | percentage change | |
| Percent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 24 | Nemolizumab (90 mg) | -69.2 | Standard Deviation 31.06 | percentage change | |
| Number of Participants Achieving Pruritus Categorical Scale (PCS) Success (Defined as a Weekly Prorated Rounded Average PCS ≤1 [None - Mild]) at Week 24 | Placebo | 13 | Participants | ||
| Number of Participants Achieving Pruritus Categorical Scale (PCS) Success (Defined as a Weekly Prorated Rounded Average PCS ≤1 [None - Mild]) at Week 24 | Nemolizumab (10 mg) | 23 | Participants | ||
| Number of Participants Achieving Pruritus Categorical Scale (PCS) Success (Defined as a Weekly Prorated Rounded Average PCS ≤1 [None - Mild]) at Week 24 | Nemolizumab (30 mg) | 31 | Participants | ||
| Number of Participants Achieving Pruritus Categorical Scale (PCS) Success (Defined as a Weekly Prorated Rounded Average PCS ≤1 [None - Mild]) at Week 24 | Nemolizumab (90 mg) | 20 | Participants | ||
| Number of Participants With an Improvement of Weekly Average Peak Pruritus Numeric Rating Scale (NRS) ≥4 at Each Timepoint up to Week 24 | Placebo | Week 1 | 3 | Participants | |
| Number of Participants With an Improvement of Weekly Average Peak Pruritus Numeric Rating Scale (NRS) ≥4 at Each Timepoint up to Week 24 | Nemolizumab (10 mg) | Week 1 | 9 | Participants | |
| Number of Participants With an Improvement of Weekly Average Peak Pruritus Numeric Rating Scale (NRS) ≥4 at Each Timepoint up to Week 24 | Nemolizumab (30 mg) | Week 1 | 10 | Participants | |
| Number of Participants With an Improvement of Weekly Average Peak Pruritus Numeric Rating Scale (NRS) ≥4 at Each Timepoint up to Week 24 | Nemolizumab (90 mg) | Week 1 | 6 | Participants | |
| Number of Participants With an Improvement of Weekly Average Peak Pruritus Numeric Rating Scale (NRS) ≥4 at Each Timepoint up to Week 24 | Placebo | Week 2 | 6 | Participants | |
| Number of Participants With an Improvement of Weekly Average Peak Pruritus Numeric Rating Scale (NRS) ≥4 at Each Timepoint up to Week 24 | Nemolizumab (10 mg) | Week 2 | 19 | Participants | |
| Number of Participants With an Improvement of Weekly Average Peak Pruritus Numeric Rating Scale (NRS) ≥4 at Each Timepoint up to Week 24 | Nemolizumab (30 mg) | Week 2 | 21 | Participants | |
| Number of Participants With an Improvement of Weekly Average Peak Pruritus Numeric Rating Scale (NRS) ≥4 at Each Timepoint up to Week 24 | Nemolizumab (90 mg) | Week 2 | 17 | Participants | |
| Number of Participants With an Improvement of Weekly Average Peak Pruritus Numeric Rating Scale (NRS) ≥4 at Each Timepoint up to Week 24 | Placebo | Week 4 | 4 | Participants | |
| Number of Participants With an Improvement of Weekly Average Peak Pruritus Numeric Rating Scale (NRS) ≥4 at Each Timepoint up to Week 24 | Nemolizumab (10 mg) | Week 4 | 19 | Participants | |
| Number of Participants With an Improvement of Weekly Average Peak Pruritus Numeric Rating Scale (NRS) ≥4 at Each Timepoint up to Week 24 | Nemolizumab (30 mg) | Week 4 | 27 | Participants | |
| Number of Participants With an Improvement of Weekly Average Peak Pruritus Numeric Rating Scale (NRS) ≥4 at Each Timepoint up to Week 24 | Nemolizumab (90 mg) | Week 4 | 22 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03100344/results